文献速递产科母胎医学

足月妊娠子痫前期新定义对不良母婴结局识别的影响

Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes.
PubMed 文献 · Am J Obstet Gynecol · 2020-11-06

这项前瞻性队列研究在英格兰两家产科医院纳入15,248例单胎妊娠,比较五种子痫前期定义对足月妊娠不良母婴结局的识别能力。结果显示,国际妊娠高血压研究学会(ISSHP)母胎因素加血管生成失衡定义识别的不良结局比例最高,优于传统定义和美国妇产科医师学会(ACOG)定义。

要点

  • ISSHP母胎因素加血管生成失衡定义识别严重高血压的比例为66.9%,高于传统定义的40.6%(P<.0001)。
  • 该定义识别围产期死亡或严重新生儿疾病复合结局的比例为71.1%,传统定义为46.9%(P=.002)。
  • 该定义识别新生儿入院≥48小时的比例为73.4%,传统定义为51.4%(P=.001)。

核心结论

  • 与传统定义相比,宽泛的子痫前期定义能更好地识别有不良结局风险的妇女和婴儿。
  • 与ACOG定义相比,更包容的ISSHP母体终末器官功能障碍定义似乎更敏感。
  • 在宽泛定义中加入子宫胎盘功能障碍可优化风险识别,尤其是纳入血管生成因素时。

研究设计与样本

  • 前瞻性队列研究,在英格兰两家产科医院进行。
  • 纳入15,248例单胎妊娠,孕妇在35 0/7至36 6/7周进行常规医院访视时接受评估。
  • 评估包括病史、超声估计胎儿体重、子宫动脉/脐动脉/胎儿大脑中动脉搏动指数多普勒测量及血清PlGF与sFlt-1比值。
  • 子痫前期按五种定义分别判定:传统定义(新发蛋白尿)、ACOG 2013定义、ISSHP母体因素定义、ISSHP母胎因素定义、ISSHP母胎因素加血管生成失衡定义。
  • 比较各定义对严重母体高血压、主要母体疾病、围产期死亡或严重新生儿疾病、新生儿入院≥48小时及出生体重<第10百分位的检出率,采用卡方检验,P<.05为显著。

主要发现

  • 子痫前期识别人数随定义变化:传统定义15/281(1.8%),ACOG定义15/326(2.1%),ISSHP母体因素定义15/400(2.6%),ISSHP母胎因素定义15/434(2.8%),ISSHP母胎因素加血管生成失衡定义15/500(3.3%)。
  • 严重高血压识别率:传统定义40.6%,ISSHP母胎因素加血管生成失衡定义66.9%(P<.0001),ISSHP母胎因素定义59.2%(P=.004),ISSHP母体因素定义56.2%(P=.013),ACOG定义46.1%(P=.449)。
  • 母体严重不良事件复合结局识别率:传统定义72.2%,其余所有定义均为100%(P=.046)。
  • 围产期死亡和疾病复合结局识别率:传统定义46.9%,ISSHP母胎因素加血管生成失衡定义71.1%(P=.002),ISSHP母胎因素定义62.2%(P=.06),ISSHP母体因素定义59.8%(P=.117),ACOG定义49.4%(P=.875)。
  • 新生儿入院≥48小时识别率:传统定义51.4%,ISSHP母胎因素加血管生成失衡定义73.4%(P=.001),ISSHP母胎因素定义64.5%(P=.070),ISSHP母体因素定义60.7%(P=.213),ACOG定义53.3%(P=.890)。

关键数值与推荐

  • 传统定义:新发蛋白尿。
  • ACOG 2013定义。
  • ISSHP母体因素定义。
  • ISSHP母胎因素定义:母体因素加胎儿死亡或胎儿生长受限(根据35 0/7至36 6/7周扫描,估计胎儿体重<第3百分位,或估计胎儿体重第3至第10百分位且合并子宫动脉搏动指数>第95百分位、脐动脉搏动指数>第95百分位或大脑中动脉搏动指数<第5百分位中任一)。
  • ISSHP母胎因素加血管生成失衡定义:母胎因素加PlGF<第5百分位或sFlt-1与PlGF比值>第95百分位。

临床怎么用

  • 在足月妊娠风险识别中,可考虑采用更宽泛的ISSHP定义,尤其是纳入母胎因素和血管生成失衡指标。
  • 与传统定义和ACOG定义相比,ISSHP母胎因素加血管生成失衡定义能识别更多有不良结局风险的妇女和婴儿。
  • 临床评估时应关注子宫胎盘功能障碍和血管生成失衡标志物,以提高风险分层敏感性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Any definition of preeclampsia should identify women and babies at greatest risk of adverse outcomes. OBJECTIVE: This study aimed to investigate the ability of the American College of Obstetricians and Gynecologists and International Society for the Study of Hypertension in Pregnancy definitions of preeclampsia at term gestational age (≥37 0/7 weeks) to identify adverse maternal and perinatal outcomes. STUDY DESIGN: In this prospective cohort study at 2 maternity hospitals in England, women attending a routine hospital visit at 35 0/7 to 36 6/7 weeks' gestation underwent assessment that included history; ultrasonographic estimated fetal weight; Doppler measurements of the pulsatility index in the uterine, umbilical, and fetal middle cerebral arteries; and serum placental growth factor-to-soluble fms-like tyrosine kinase-1 ratio. Obstetrical records were examined for all women with chronic hypertension and those who developed new-onset hypertension, with preeclampsia (de novo or superimposed on chronic hypertension) defined in 5 ways: traditional, based on new-onset proteinuria; American College of Obstetricians and Gynecologists 2013 definition; International Society for the Study of Hypertension in Pregnancy maternal factors definition; International Society for the Study of Hypertension in Pregnancy maternal factors plus fetal death or fetal growth restriction definition, defined according to the 35 0/7 to 36 6/7 weeks' gestation scan as either estimated fetal weight <3rd percentile or estimated fetal weight at the 3rd to 10th percentile with any of uterine artery pulsatility index >95th percentile, umbilical artery pulsatility index >95th percentile, or middle cerebral artery pulsatility index <5th percentile; and International Society for the Study of Hypertension in Pregnancy maternal-fetal factors plus angiogenic imbalance definition, defined as placental growth factor <5th percentile or soluble fms-like tyrosine kinase-1-to-serum placental growth factor >95th percentile. Detection rates for outcomes of interest (ie, severe maternal hypertension, major maternal morbidity, perinatal mortality or major neonatal morbidity, neonatal unit admission ≥48 hours, and birthweight <10th percentile) were compared using the chi-square test, and P<.05 was considered significant. RESULTS: Among 15,248 singleton pregnancies, the identification of women with preeclampsia varied by definition: traditional, 15 of 281 (1.8%; 248); American College of Obstetricians and Gynecologists, 15 of 326 (2.1%; 248); International Society for the Study of Hypertension in Pregnancy maternal factors, 15 of 400 (2.6%; 248); International Society for the Study of Hypertension in Pregnancy maternal-fetal factors, 15 of 434 (2.8%; 248); and International Society for the Study of Hypertension in Pregnancy maternal-fetal factors plus angiogenic imbalance, 15 of 500 (3.3%; 248). Compared with the traditional definition of preeclampsia, the International Society for the Study of Hypertension in Pregnancy maternal-fetal factors plus angiogenic imbalance best identified the adverse outcomes: severe hypertension (40.6% [traditional] vs 66.9% [International Society for the Study of Hypertension in Pregnancy maternal-fetal factors plus angiogenic imbalance, P<.0001], 59.2% [International Society for the Study of Hypertension in Pregnancy maternal-fetal factors, P=.004], 56.2% [International Society for the Study of Hypertension in Pregnancy maternal factors, P=.013], 46.1% [American College of Obstetricians and Gynecologists, P=.449]); P<.0001); composite maternal severe adverse event (72.2% [traditional] vs 100% for all others; P=.046); composite of perinatal mortality and morbidity (46.9% [traditional] vs 71.1% [International Society for the Study of Hypertension in Pregnancy maternal-fetal factors plus angiogenic imbalance, P=.002], 62.2% [International Society for the Study of Hypertension in Pregnancy maternal-fetal factors, P=.06], 59.8% [International Society for the Study of Hypertension in Pregnancy maternal factors, P=.117], 49.4% [American College of Obstetricians and Gynecologists, P=.875]); neonatal unit admission for ≥48 hours (51.4% [traditional] vs 73.4% [International Society for the Study of Hypertension in Pregnancy maternal-fetal factors plus angiogenic imbalance, P=.001], 64.5% [International Society for the Study of Hypertension in Pregnancy maternal-fetal factors, P=.070], 60.7% [International Society for the Study of Hypertension in Pregnancy maternal factors, P=.213], 53.3% [American College of Obstetricians and Gynecologists, P=.890]); birthweight <10th percentile (40.5% [traditional] vs 78.7% [International Society for the Study of Hypertension in Pregnancy maternal-fetal factors plus angiogenic imbalance, P<.0001], 70.1% [International Society for the Study of Hypertension in Pregnancy maternal-fetal, P<.0001], 51.3% [International Society for the Study of Hypertension in Pregnancy maternal factors, P=.064], 46.3% [American College of Obstetricians and Gynecologists, P=.349]). CONCLUSION: Our findings present an evidence base for the broad definition of preeclampsia. Our data suggest that compared with a traditional definition, a broad definition of preeclampsia can better identify women and babies at risk of adverse outcomes. Compared with the American College of Obstetricians and Gynecologists definition, the more inclusive International Society for the Study of Hypertension in Pregnancy definition of maternal end-organ dysfunction seems to be more sensitive. The addition of uteroplacental dysfunction to the broad definition optimizes the identification of women and babies at risk, particularly when angiogenic factors are included.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Lai J, Syngelaki A, Nicolaides KH, et al. Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes. Am J Obstet Gynecol. 2020. PMID: 33166504. doi:10.1016/j.ajog.2020.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。